These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 26980046

  • 1. Impact of peritumoral and intratumoral budding in esophageal adenocarcinomas.
    Thies S, Guldener L, Slotta-Huspenina J, Zlobec I, Koelzer VH, Lugli A, Kröll D, Seiler CA, Feith M, Langer R.
    Hum Pathol; 2016 Jun; 52():1-8. PubMed ID: 26980046
    [Abstract] [Full Text] [Related]

  • 2. The prognostic importance of immunohistochemically detected node metastases in resected esophageal adenocarcinoma.
    Waterman TA, Hagen JA, Peters JH, DeMeester SR, Taylor CR, Demeester TR.
    Ann Thorac Surg; 2004 Oct; 78(4):1161-9; discussion 1161-9. PubMed ID: 15464464
    [Abstract] [Full Text] [Related]

  • 3. Tumor Budding Detection by Immunohistochemical Staining is Not Superior to Hematoxylin and Eosin Staining for Predicting Lymph Node Metastasis in pT1 Colorectal Cancer.
    Okamura T, Shimada Y, Nogami H, Kameyama H, Kobayashi T, Kosugi S, Wakai T, Ajioka Y.
    Dis Colon Rectum; 2016 May; 59(5):396-402. PubMed ID: 27050601
    [Abstract] [Full Text] [Related]

  • 4. Prognostic significance of peritumoural and intratumoural budding in intestinal-type gastric adenocarcinoma.
    Qi B, Liu L, Pan Y, Xu S, Li J.
    Arab J Gastroenterol; 2020 Jun; 21(2):111-116. PubMed ID: 32423856
    [Abstract] [Full Text] [Related]

  • 5. Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma.
    O'Connor K, Li-Chang HH, Kalloger SE, Peixoto RD, Webber DL, Owen DA, Driman DK, Kirsch R, Serra S, Scudamore CH, Renouf DJ, Schaeffer DF.
    Am J Surg Pathol; 2015 Apr; 39(4):472-8. PubMed ID: 25634751
    [Abstract] [Full Text] [Related]

  • 6. Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches.
    Karamitopoulou E, Thies S, Zlobec I, Ott K, Feith M, Slotta-Huspenina J, Lordick F, Becker K, Langer R.
    Am J Surg Pathol; 2014 Nov; 38(11):1551-6. PubMed ID: 25140894
    [Abstract] [Full Text] [Related]

  • 7. Intratumoral budding: A novel prognostic biomarker for tumor recurrence and a potential predictor of nodal metastasis in uterine cervical cancer.
    Chong GO, Jee-Young Park N, Han HS, Cho J, Kim MG, Choi Y, Yeo JY, Lee YH, Hong DG, Park JY.
    Eur J Surg Oncol; 2021 Dec; 47(12):3182-3187. PubMed ID: 34284905
    [Abstract] [Full Text] [Related]

  • 8. Tumour budding as a prognostic biomarker in biopsies and resections of neoadjuvant-treated rectal adenocarcinoma.
    Aherne S, Donnelly M, Ryan ÉJ, Davey MG, Creavin B, McGrath E, McCarthy A, Geraghty R, Gibbons D, Nagtegaal I, Lugli A, Kirsch R, Martin ST, Winter DC, Sheahan K, collaborators at the Centre for Colorectal Disease and International Tumour Budding Consortium funded by the Dutch Cancer Society.
    Histopathology; 2024 Aug; 85(2):224-243. PubMed ID: 38629323
    [Abstract] [Full Text] [Related]

  • 9. Tumor budding assessed according to the criteria of the International Tumor Budding Consensus Conference determines prognosis in resected esophageal adenocarcinoma.
    Lohneis P, Hieggelke L, Gebauer F, Ball M, Bruns C, Büttner R, Löser H, Quaas A.
    Virchows Arch; 2021 Mar; 478(3):393-400. PubMed ID: 32761393
    [Abstract] [Full Text] [Related]

  • 10. Comprehensive assessment of tumour budding by cytokeratin staining in colorectal cancer.
    Rieger G, Koelzer VH, Dawson HE, Berger MD, Hädrich M, Inderbitzin D, Lugli A, Zlobec I.
    Histopathology; 2017 Jun; 70(7):1044-1051. PubMed ID: 28061021
    [Abstract] [Full Text] [Related]

  • 11. Comparison between Peritumoral and Intratumoral Budding in Colorectal Cancer.
    Pyo JS, Choi JE, Kim NY, Min KW, Kang DW.
    Biomedicines; 2024 Jan 17; 12(1):. PubMed ID: 38255317
    [Abstract] [Full Text] [Related]

  • 12. Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival.
    Singhi AD, Foxwell TJ, Nason K, Cressman KL, McGrath KM, Sun W, Bahary N, Zeh HJ, Levy RM, Luketich JD, Davison JM.
    Am J Surg Pathol; 2015 Apr 17; 39(4):487-95. PubMed ID: 25634752
    [Abstract] [Full Text] [Related]

  • 13. Accumulation of FOXP3+T-cells in the tumor microenvironment is associated with an epithelial-mesenchymal-transition-type tumor budding phenotype and is an independent prognostic factor in surgically resected pancreatic ductal adenocarcinoma.
    Wartenberg M, Zlobec I, Perren A, Koelzer VH, Gloor B, Lugli A, Karamitopoulou E.
    Oncotarget; 2015 Feb 28; 6(6):4190-201. PubMed ID: 25669968
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of venous invasion by Elastica van Gieson stain and tumor budding predicts local and distant metastases in patients with T1 stage colorectal cancer.
    Suzuki A, Togashi K, Nokubi M, Koinuma K, Miyakura Y, Horie H, Lefor AT, Yasuda Y.
    Am J Surg Pathol; 2009 Nov 28; 33(11):1601-7. PubMed ID: 19574884
    [Abstract] [Full Text] [Related]

  • 15. Tumor budding is predictive of lymphatic involvement and lymph node metastases in submucosal invasive colorectal adenocarcinomas and in non-polypoid compared with polypoid growths.
    Ogawa T, Yoshida T, Tsuruta T, Tokuyama W, Adachi S, Kikuchi M, Mikami T, Saigenji K, Okayasu I.
    Scand J Gastroenterol; 2009 Nov 28; 44(5):605-14. PubMed ID: 19221929
    [Abstract] [Full Text] [Related]

  • 16. Immunohistochemical analysis of tumor budding as predictor of lymph node metastasis from superficial esophageal squamous cell carcinoma.
    Fuchinoue K, Nemoto T, Shimada H, Tochigi N, Igarashi Y, Yajima S, Suzuki T, Oshima Y, Shibuya K.
    Esophagus; 2020 Apr 28; 17(2):168-174. PubMed ID: 31595396
    [Abstract] [Full Text] [Related]

  • 17. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
    Voss SM, Riley MP, Lokhandwala PM, Wang M, Yang Z.
    Am J Surg Pathol; 2015 Jan 28; 39(1):13-24. PubMed ID: 25353284
    [Abstract] [Full Text] [Related]

  • 18. High-grade intratumoral tumor budding is a predictor for lymphovascular invasion and adverse outcome in stage II colorectal cancer.
    Marx AH, Mickler C, Sauter G, Simon R, Terracciano LM, Izbicki JR, Clauditz TS.
    Int J Colorectal Dis; 2020 Feb 28; 35(2):259-268. PubMed ID: 31838579
    [Abstract] [Full Text] [Related]

  • 19. Prognostic significance of tumor budding, desmoplastic reaction, and lymphocytic infiltration in patients with gastric adenocarcinoma.
    Yavuz A, Simsek K, Alpsoy A, Altunay B, Gedik EO, Unal B, Bassorgun CI, Tatli AM, Elpek GO.
    World J Gastrointest Pathophysiol; 2024 Apr 22; 15(1):91237. PubMed ID: 38682027
    [Abstract] [Full Text] [Related]

  • 20. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients.
    Lugli A, Vlajnic T, Giger O, Karamitopoulou E, Patsouris ES, Peros G, Terracciano LM, Zlobec I.
    Hum Pathol; 2011 Dec 22; 42(12):1833-40. PubMed ID: 21664647
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.